Nitecapone (OR-462) is a drug which acts as a selective inhibitor of the enzyme catechol O-methyl transferase (COMT).It was patented as an antiparkinson medication.
Nitecapone (1-100 μM) reducesd GSH (reduced glutathione) depletion induced by ROO-by 11-38% and oxidation to oxidized glutathione (GSSG) by 32-45%.MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Nitecapone (OR-462) is a short-acting, orally active, catechol-O-methyltransferase (COMT) inhibitor with gastrointestinal protective and antioxidant activity. Nitecapone (OR-462) scavenges reactive oxygen species and nitric oxide and prevents lipid peroxidation.
Inhibitor for the treatment of Parkinson disease
Inhibitor for the treatment of Parkinson's disease.
ChEBI: Nitecapone is a hydroxycinnamic acid.
